Page last updated: 2024-11-13

vulpinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vulpinic acid: RN given refers to cpd without isomeric designation; structure given in first source; vulpinic acid refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54690323
CHEMBL ID463212
CHEBI ID144250
SCHEMBL ID559925
SCHEMBL ID559924
MeSH IDM0207243

Synonyms (48)

Synonym
vulpinic acid
2, 3,4-dihydroxy-2,5-diphenyl-, mono-.gamma.-lactone, methyl ester
.delta.2(5h), 3-hydroxy-5-oxo-.alpha.,4-diphenyl-, methyl ester
wln: t5voyj cuyr&vo1 dq er
benzeneacetic acid, methyl ester, (e)-
521-52-8
nsc-5897
.delta.(sup 2(5h), 3-hydroxy-5-oxo-.alpha.,4-diphenyl-, methyl ester
nsc5897 ,
2-(2,5-dihydro-3-hydroxy-5-oxo-4-phenyl-2-furanylidene)-2-phenylacetic acid methyl ester
acetic acid, 2-(2,5-dihydro-3-hydroxy-5-oxo-4-phenyl-2-furanylidene)-2-phenyl-, methyl ester
brn 1437166
nsc 5897
acetic acid, (3-hydroxy-5-oxo-4-phenyl-2(5h)-furylidene)phenyl-, methyl ester
vulpic acid
NCGC00160145-01
CHEMBL463212
CHEBI:144250
73622-57-8
SCHEMBL559925
SCHEMBL559924
3,4-dihydroxy-2,5-diphenyl-2,4-hexadienedioic acid methyl ester 3,6-lactone
CCG-208551
methylpulvinsaure
benzeneacetic acid, .alpha.-(3-hydroxy-5-oxo-4-phenyl-2(5h)-furanylidene)-, methyl ester, (e)-
.delta.(sup 2(5h),.alpha.)-furanacetic acid, 3-hydroxy-5-oxo-.alpha.,4-diphenyl-, methyl ester
2,4-hexadienedioic acid, 3,4-dihydroxy-2,5-diphenyl-, mono-.gamma.-lactone, methyl ester
.delta.2(5h),.alpha.-furanacetic acid, 3-hydroxy-5-oxo-.alpha.,4-diphenyl-, methyl ester
OMZRMXULWNMRAE-BMRADRMJSA-N
methyl (2e)-(3-hydroxy-5-oxo-4-phenyl-2(5h)-furanylidene)(phenyl)ethanoate #
benzeneacetic acid, .alpha.-(3-hydroxy-5-oxo-4-phenyl-2(5h)-furanylidene)-, methyl ester
pulvinic acid methyl ester
mfcd00075804
methyl (2e)-(3-hydroxy-5-oxo-4-phenyl-2(5h)-furanylidene)(phenyl)ethanoate
sr-05000002200
SR-05000002200-2
SR-05000002200-3
bdbm50478424
methyl (e)-2-(3-hydroxy-5-oxo-4-phenylfuran-2(5h)-ylidene)-2-phenylacetate
AKOS030632335
methyl (z)-2-(3-hydroxy-5-oxo-4-phenylfuran-2(5h)-ylidene)-2-phenylacetate
(e)-methyl 2-(3-hydroxy-5-oxo-4-phenylfuran-2(5h)-ylidene)-2-phenylacetate
antimonytetrachloromonofluoride
methyl (2e)-2-(3-hydroxy-5-oxo-4-phenylfuran-2-ylidene)-2-phenylacetate
(alphae)-alpha-(3-hydroxy-5-oxo-4-phenyl-2(5h)-furanylidene)benzeneacetic acid methyl ester
HY-125919
CS-0103068
DTXSID601027308
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
butenolideA gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00500.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
Microtubule-associated protein tauHomo sapiens (human)Potency0.22390.180013.557439.8107AID1460
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Enoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12IC50 (µMol)84.00000.00501.576510.0000AID751284
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
lipid biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid elongationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein homotetramerizationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
biotin biosynthetic processEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
fatty acid elongationEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
response to antibioticEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
enoyl-[acyl-carrier-protein] reductase (NADH) activityEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
oxidoreductase activityEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
identical protein bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
NADH bindingEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
membraneEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
protein-containing complexEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
catalytic complexEnoyl-[acyl-carrier-protein] reductase [NADH] FabIEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID751281Antibacterial activity against Escherichia coli ATCC 87392013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751280Toxicity in zebrafish larva measured at 4 days postfertilization2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751293Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as decrease in size at 10 uM after 48 hrs by immunofluorescence analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751289Inhibition of Plasmodium falciparum FabI using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID415081Antioxidant activity against UV/H2O2-induced thymidine degradation at 100 uM by thymidine protection assay2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Evaluation of antioxidant properties of monoaromatic derivatives of pulvinic acids.
AID751294Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as reduction in PB18S gene expression after 48 hrs by qRT-PCR analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751286Inhibition of Mycobacterium tuberculosis FabI using 2-dodecenoyl-CoA as substrate at pH 6.82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751285Inhibition of Staphylococcus aureus FabI using dodecenoyl ACP at pH 7.82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID751288Inhibition of Plasmodium falciparum FabG using acetoacetyl-CoA as substrate2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751287Inhibition of Plasmodium falciparum FabZ using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751295Cytotoxicity against human Huh7.5 cells after 24 hrs by Cell-titerGlo luminescence assay2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751291Antiplasmodial activity against blood stage of chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 after 48 hrs by [3H]-hypoxanthine incorporation assay2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID414853Antioxidant activity against Fe/EDTA/H2O2-induced thymidine degradation at 100 uM by thymidine protection assay2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Evaluation of antioxidant properties of monoaromatic derivatives of pulvinic acids.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID751276Hepatotoxicity in zebrafish larva expressing fabp10a:DsRed2 assessed as change in liver size at 3.6 to 60.2 uM measured at 6 days postfertilization by fluorescence microscopic analysis relative to control2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID334198Inhibition of COX12003Journal of natural products, Jan, Volume: 66, Issue:1
Chemical and biological investigation of the fungus Pulveroboletus ravenelii.
AID751284Inhibition of Escherichia coli FabI using 2-dodecenoyl-CoA as substrate at pH 82013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751282Antibacterial activity against Staphylococcus aureus ATCC 65382013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751278Hepatotoxicity in zebrafish larva expressing fabp10a:DsRed2 assessed as enlargement of liver at 15.5 uM measured at 6 days postfertilization by fluorescence microscopic analysis2013Journal of natural products, Jun-28, Volume: 76, Issue:6
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID334200Inhibition of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesions in BALB/c mouse mammary gland culture after 1 to 10 days2003Journal of natural products, Jan, Volume: 66, Issue:1
Chemical and biological investigation of the fungus Pulveroboletus ravenelii.
AID334197Antimicrobial activity against Staphylococcus aureus2003Journal of natural products, Jan, Volume: 66, Issue:1
Chemical and biological investigation of the fungus Pulveroboletus ravenelii.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.13)18.7374
1990's3 (9.38)18.2507
2000's7 (21.88)29.6817
2010's14 (43.75)24.3611
2020's7 (21.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.86 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]